Table 5.

Analysis of the results of studies listed in Table 4.

Publication	Patient population	Endpoints/definition of CIN	Contrast media	Results
Carraro et al. [32]	Patients with mild to moderate CRI	SCr ≥50% 24 h after administration	Iodixanol 320 (N=32) Iopromide 300 (N=32)	No significant difference
Chuang et al. [33]	Patients with CRI and/or diabetes	SCr ≥25% 72 h after administration	Iodixanol* (N=25) Iohexol* (N=25) *mgI/mL not available	No significant difference
Barrett et al. [34]	Patients with moderate to severe CRI	SCr ≥0.5 mg/dL 48–72 h after administration	Iodixanol 320 (N=76) Iopamidol 370 (N=77) Dose: 40 g I	No significant difference (2.6% vs. 0, p=0.3)
Thomsen et al. [35]	Patients with moderate to severe CRI	SCr ≥0.5 mg/dL 48–72 h after administration	Iodixanol 320 (N=72) Iomeprol 400 (N=76) Dose: 40 g I	Ioversol > Iomeprol (6.9% vs. 2.5%, p < 0.03)
Nguyen et al. [36]	Patients with moderate to severe CRI	SCr ≥0.5 mg/dL 24, 48 and 72 h after administration	Iodixanol 320 (N=61) Iopromide 370 (N=56) Dose: 37 g I	Iohexol > Iopromide (5.1% vs. 18.6%, p<0.04)
Kuhn et al. [37]	Patients with moderate to severe CRI	SCr ≥25% 48–72 h after administration	Iodixanol 320 (N=123) Iopamiron 370 (N=125) Dose: Iodixanol 32.5 g I Iopamidol 39.4 g I	No significant difference (4.9% vs. 5.6, p=1.0)
Zo’o et al. [38]	Pediatric patients (aged 1–16) with normal renal function	SCr ≥0.5 mg/dL 48–72 h after administration	Iodixanol 270 (N=71) Iobitridol 300 (N=74)	No significant difference (ITT 10.6% vs. 4.8%, p=0.72.) PP 10.3% vs. 0%, p=0.68)